April 11, 2025

The American College of Radiology® (ACR®) provided comments to the U.S. Food and Drug Administration (FDA) regarding the agency’s draft guidance to address risk management approaches throughout the lifecycle of AI-enabled medical devices, including radiology AI. The document discusses information that manufacturers should share with FDA reviewers and other relevant stakeholders, including physicians and practices, to help them evaluate and monitor AI tools’ safety and effectiveness.

ACR’s comment letter supported the advancement of safe, effective, and clinically useful AI innovation. The College recommended further specificity in product information provided by manufacturers and regulators regarding clinical end-user qualifications. For example, radiologist end-users of imaging AI tools help mitigate risk because they are qualified to interpret imaging examinations without AI assistance. ACR also recommended various enhancements to the guidance’s content on site-level validation, performance monitoring and AI types with novel oversight considerations.  

For more information about ACR’s AI-related initiatives, visit the ACR DSI website. For questions about AI oversight and digital health policy, contact Michael Peters, ACR Senior Director, Government Affairs.


Related ACR News

  • Federal Government Shutdown: Key Updates

    Key information and resources for ACR members regarding the October 2025 U.S. federal government shutdown.

    Read more
  • CMS Appears to Lift Majority of Medicare Claims Holds

    The most recent update by CMS directs MACs to lift the hold on certain services impacted by select expired Medicare legislative payment provisions.

    Read more
  • Urge Your Representative to Cosponsor ROOT Act Today

    ACR urges support for H.R. 5737, the ROOT Act, to fix CMS imaging rules and save Medicare billions. Contact your rep to cosponsor today.

    Read more